The development of biomaterial-based vaccine platforms against viruses 3SHARES Share via Pinterest Reddit Buffer Xing WhatsApp Flipboard Posted: 31 March 2021 | Dr Kaushik Chatterjee (Indian Institute of Science), Dr Sonal Asthana (Indian Institute of Science), Dr Sushma Kumari (Indian Institute of Science) | No comments yet Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases. Abstract The scientific community’s response to the COVID-19 pandemic has seen a shift of research focus towards the development of different approaches and methods to fight against infectious diseases. Novel biomaterials and nanotechnology-based vaccine formulations will play an important role in new strategies to contain viral pandemics. This article highlights the current efforts and opportunities offered by biomaterials and nanomaterials in the development of vaccines to prevent the spread of contagious diseases and tackle future outbreaks. With regular news updates and feature articles, our COVID-19 hub has everything you need to keep up to date with R&D during the pandemic. Click below to visit: COVID-19 hub To read this article in full, please complete the form below: First Name * Surname * Job Title * Organisation * Town/City * Country * —Please choose an option—AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCook IslandsCosta RicaCote D'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFaeroe IslandsFalkland IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadaloupeGuamGuatemalaGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsVatican CityHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKoreaKosovaKuwaitKyrgyz RepublicLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoryPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandPolandPortugalPuerto RicoQatarReunionRomaniaRussiaRwandaSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbia and MontenegroSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSpainSri LankaSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudanSurinameSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUnited States of AmericaUruguayUS Virgin IslandsUzbekistanVanuatuVenezuelaVietnamWallis and Futuna IslandsWestern SaharaYemenZambiaZimbabwe Email * Telephone * This specialist content is provided to you free-of-charge thanks to the kind support of GenScript and IDBS I would like to receive relevant information and insights from the sponsor(s) of this content *—Please choose an option—YesNo By clicking submit you confirm that you accept our terms and conditions and privacy policy. Related topicsAntibodies, Biopharmaceuticals, Immunology, Nanomedicine, Proteomics, t-cells, Vaccine Related conditionsCerebral malaria, Covid-19, Ebola, Flaviviruses, Hepatitis B, Hepatitis C, HIV, Influenza, Malaria, Middle East Respiratory Syndrome (MERS), Murray Valley encephalitis virus (MVEV), Severe Acute Respiratory Syndrome (SARS), West Nile Virus (WNV), Zika Related organisationsGenScript, IDBS